Cumberland and RedHill Begin Joint U.S. Rollout of Talicia With $4M Investment
Cumberland Pharmaceuticals and RedHill Biopharma have commenced the full U.S. commercial launch of Talicia via a 70/30 joint venture backed by Cumberland’s $4 million strategic investment, leveraging Cumberland’s national sales force to drive prescription growth. Talicia, the only FDA-approved all-in-one rifabutin-based H. pylori therapy and a first-line American College of Gastroenterology guideline option, is patent-protected through 2042 and addresses an estimated 1.6 million U.S. patients treated annually.
1. Launch of Joint Commercialization Model
The operational rollout of Talicia in the U.S. has commenced under Talicia Holdings Inc., a 70% RedHill/30% Cumberland joint venture supported by Cumberland’s $4 million strategic investment. This phase marks the transition from agreement signing to active co-marketing, with both partners coordinating sales and distribution activities.
2. Cumberland’s National Promotional Campaign
Cumberland has assumed full responsibility for U.S. distribution and sales promotion, deploying its existing field sales force division and marketing initiatives to increase awareness among gastroenterologists and prescribing physicians. The campaign aims to accelerate prescription growth and expand patient access to Talicia across targeted markets.
3. Therapy Profile and Market Opportunity
Talicia is the only FDA-approved, all-in-one low-dose rifabutin-based H. pylori therapy and is listed as a first-line treatment in the 2024 ACG Clinical Guideline. H. pylori affects 35% of U.S. adults, with approximately 1.6 million patients treated annually; Talicia holds U.S. patent protection through 2042 and eight years of market exclusivity under QIDP designation.